Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative ColitisWilliam J. Sandborn, Paul Rutgeerts, Brian G. Feagan et al.|Gastroenterology|2013Cited by 938
Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative ColitisWilliam J. Sandborn, Paul Rutgeerts, Judith Collins et al.|Gastroenterology|2013Cited by 725
Maintenance of Efficacy and Continuing Safety of Golimumab for Active Ulcerative Colitis: PURSUIT-SC Maintenance Study Extension Through 1 YearWalter Reinisch, Brian G. Feagan, William J. Sandborn et al.|Clinical and Translational Gastroenterology|2016Cited by 40
Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance ExtensionWalter Reinisch, Colleen Marano, William J. Sandborn et al.|Journal of Crohn s and Colitis|2018Cited by 35
Clinical Response Is a Meaningful Endpoint in Ulcerative Colitis Clinical StudiesWilliam J. Sandborn, Paul Rutgeerts, Brian Feagan et al.|Inflammatory Bowel Diseases|2012Cited by 3